These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24756790)

  • 1. Sorafenib: targeting multiple tyrosine kinases in cancer.
    Hasskarl J
    Recent Results Cancer Res; 2014; 201():145-64. PubMed ID: 24756790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib.
    Hasskarl J
    Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib and thyroid cancer.
    Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
    BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
    Smolle E; Taucher V; Petru E; Haybaeck J
    Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The adverse effects of sorafenib in patients with advanced cancers.
    Li Y; Gao ZH; Qu XJ
    Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):216-21. PubMed ID: 25495944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggressive thyroid cancer: targeted therapy with sorafenib.
    Corrado A; Ferrari SM; Politti U; Mazzi V; Miccoli M; Materazzi G; Antonelli A; Ulisse S; Fallahi P; Miccoli P
    Minerva Endocrinol; 2017 Mar; 42(1):64-76. PubMed ID: 26112458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib in patients with refractory or recurrent multiple myeloma.
    Yordanova A; Hose D; Neben K; Witzens-Harig M; Gütgemann I; Raab MS; Moehler T; Goldschmidt H; Schmidt-Wolf IG
    Hematol Oncol; 2013 Dec; 31(4):197-200. PubMed ID: 23494836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib for ovarian cancer.
    Leone Roberti Maggiore U; Valenzano Menada M; Venturini PL; Ferrero S
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1049-62. PubMed ID: 23675696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
    Peng S; Wang Y; Peng H; Chen D; Shen S; Peng B; Chen M; Lencioni R; Kuang M
    Hepatology; 2014 Oct; 60(4):1264-77. PubMed ID: 24849467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
    Gill H; Man CH; Ip AH; Choi WW; Chow HC; Kwong YL; Leung AY
    Haematologica; 2015 Jul; 100(7):e250-3. PubMed ID: 25820334
    [No Abstract]   [Full Text] [Related]  

  • 11. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
    Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E
    Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib for the treatment of multiple myeloma.
    Gentile M; Martino M; Recchia AG; Vigna E; Morabito L; Morabito F
    Expert Opin Investig Drugs; 2016 Jun; 25(6):743-9. PubMed ID: 26998658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
    Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
    Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
    [No Abstract]   [Full Text] [Related]  

  • 14. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
    Delire B; Stärkel P
    Eur J Clin Invest; 2015 Jun; 45(6):609-23. PubMed ID: 25832714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.
    Qiu YQ; Zhou J; Kang XS; Shen-Tu JZ; Ding LM; Tan FL; Guo J; Li LJ
    Afr J Tradit Complement Altern Med; 2012; 9(3):431-9. PubMed ID: 23983378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib in renal cell carcinoma.
    Davoudi ET; bin-Noordin MI; Javar HA; Kadivar A; Sabeti B
    Pak J Pharm Sci; 2014 Jan; 27(1):203-8. PubMed ID: 24374450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors.
    Tamiya H; Kamo R; Kumei A; Yanagihara S; Ishii M; Kobayashi H
    Clin Exp Dermatol; 2012 Oct; 37(7):749-52. PubMed ID: 22369131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib (Nexavar) for thyroid cancer.
    Med Lett Drugs Ther; 2014 May; 56(1443):43-4. PubMed ID: 24869715
    [No Abstract]   [Full Text] [Related]  

  • 19. Regorafenib.
    Ettrich TJ; Seufferlein T
    Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
    Li J; Wang L; Cong N; Shi C; Bu W; Song J; Chen H
    Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.